Ken Griffin Intellia Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 186,800 shares of NTLA stock, worth $2.16 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
186,800
Previous 102,100
82.96%
Holding current value
$2.16 Million
Previous $725,000
141.66%
% of portfolio
0.0%
Previous 0.0%
Shares
31 transactions
Others Institutions Holding NTLA
# of Institutions
333Shares Held
97.2MCall Options Held
1.66MPut Options Held
1.03M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$151 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$126 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$111 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.12MShares$47.6 Million0.0% of portfolio
-
State Street Corp Boston, MA4.04MShares$46.7 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $879M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...